Andreas Halvorsen's Viking Global Buys Oncothyreon (ONTY) ~ market folly

Tuesday, September 27, 2011

Andreas Halvorsen's Viking Global Buys Oncothyreon (ONTY)

Andreas Halvorsen's hedge fund Viking Global filed a 13G with the SEC regarding shares of Oncothyreon (ONTY).

Viking has revealed a 7.1% ownership stake in the company with 2,960,650 shares. This is a brand new position for the hedge fund as they did not report owning a stake at the end of the second quarter.

Remember that all SEC filings are made on a delayed basis, so while their filing says this activity occurred on September 14th, they weren't required to file with the SEC until yesterday.

This is the only 13G or 13D filing we've seen from Viking since we detailed they ramped up their position in Universal Health Services (UHS) back in April.

Per Google Finance, Oncothyreon is "a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. Oncothyreon’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins.

The Company’s lead product candidate under clinical development is a vaccine it calls Stimuvax. Stimuvax incorporates a 25 amino acid sequence of the cancer antigen MUC1, in a liposomal formulation. Stimuvax is designed to induce an immune response to destroy cancer cells that express MUC1, a protein antigen widely expressed on many common cancers, such as lung cancer, breast cancer and colorectal cancer. Oncothyreon has granted an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax."

blog comments powered by Disqus